August 23, 2012 08:00 ET

Equity Research on Elan Corp. plc and Hospira Inc. - Currency Movements Weigh on Drug Delivery Industry

NEW YORK, NY--(Marketwire - Aug 23, 2012) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drug Delivery industry and are offering free analytical research on Elan Corp. plc (NYSE: ELN) and Hospira Inc. (NYSE: HSP). Register with us now to have free access to these research reports. Simply click on the link below.

Companies within the drug delivery industry have fared well in recent weeks as efforts to expand globally are leading to greater overseas revenues. Fluctuating currency markets have been a big downside to these efforts though as unfavorable translations continue to work against the industry. Get your free reports on Elan Corp. plc and Hospira Inc. at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Elan Corp. plc and Hospira Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing.

Greater efforts to grow sales abroad are evidenced in the latest quarterly reports from both Elan Corp. and Hospira Inc. Elan witnessed global in-market net sales of Tysabri grow 8% in the first half of the year which could have been even better had it not been for unfavorable currency exchanges in Europe. Elan Corp. plc report is accessible for free by registering today at

Similarly, Hospira saw revenue gains in the Europe, Middle-East and the African region as well as in the Asia/Pacific market. Hospira Inc. report is accessible for free by registering today at

A weaker U.S. dollar would go a long way for the drug delivery system. As it stands though, the industry continues to make progress extending its global reach, brightening the near- and long-term outlook. The two Drug Delivery stocks research reports are available for free by signing up now on the link below.


Shine's Rooms is the brain child of David Shine, a 13 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information